These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 36620596)
1. Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients. Guo Q; Qiu P; Pan K; Lin J Front Oncol; 2022; 12():1081089. PubMed ID: 36620596 [TBL] [Abstract][Full Text] [Related]
2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma. Wang S; Bai H; Fei S; Miao B Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914 [TBL] [Abstract][Full Text] [Related]
3. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients. Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS Front Oncol; 2022; 12():988680. PubMed ID: 36203428 [TBL] [Abstract][Full Text] [Related]
4. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Pan Y; Zhang Q; Zhang H; Kong F Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225 [TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma. Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708 [TBL] [Abstract][Full Text] [Related]
6. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. Wang F; Lin H; Su Q; Li C World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer. Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115 [TBL] [Abstract][Full Text] [Related]
8. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma. Huang Y; Gong P; Su L; Zhang M Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer. Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M Front Immunol; 2022; 13():891175. PubMed ID: 35990668 [TBL] [Abstract][Full Text] [Related]
10. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer. Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X Front Genet; 2023; 14():1096783. PubMed ID: 36911392 [No Abstract] [Full Text] [Related]
11. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma. Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792 [TBL] [Abstract][Full Text] [Related]
12. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia. Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F Front Oncol; 2022; 12():966920. PubMed ID: 36276132 [TBL] [Abstract][Full Text] [Related]
13. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma. Liu Y; Jiang J Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878 [TBL] [Abstract][Full Text] [Related]
14. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Xu M; Mu J; Wang J; Zhou Q; Wang J Front Oncol; 2022; 12():961213. PubMed ID: 35965536 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma. Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032 [TBL] [Abstract][Full Text] [Related]
16. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
17. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma. Ma C; Li F; Gu Z; Yang Y; Qi Y Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938 [No Abstract] [Full Text] [Related]
18. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature. Zhang N; Yu X; Sun H; Zhao Y; Wu J; Liu G Medicine (Baltimore); 2023 Oct; 102(42):e35167. PubMed ID: 37861553 [TBL] [Abstract][Full Text] [Related]
19. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma. Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612 [TBL] [Abstract][Full Text] [Related]
20. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]